Advertisement

Identification of differentially expressed genes between triple and non-triple-negative breast cancer using bioinformatics analysis

  • Qixi Zhai
  • Hao Li
  • Liping Sun
  • Yuan YuanEmail author
  • Xuemei WangEmail author
Original Article
  • 55 Downloads

Abstract

Background

Triple-negative breast cancer (TNBC), defined by lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), is characterized by early recurrence of disease and poor survival.

Objective

Here, we sought to identify genes associated with TNBC that could provide new insight into gene dysregulation in TNBC and, at the same time, provide additional potential therapeutic targets for breast cancer treatment.

Methods

Gene expression profiles from accession series GSE76275 were downloaded from the Gene Expression Omnibus database (GEO). The Cancer Genome Atlas (TCGA) was used to validate potential hub genes in the TCGA database. Protein–protein interaction (PPI) networks were identified using STRING (Search Tool for the Retrieval of Interacting Genes/Proteins). Finally, overall survival (OS) and relapse-free survival (RFS) analysis of hub genes was performed using a Kaplan–Meier plotter online tool.

Results

A total of 750 genes were identified after analysis of GSE76275. After validation with the TCGA database, a total of 155 differentially expressed genes (DEGs) were consistent with those identified by GSE76275. Based on the STRING database, we constructed a PPI network using the DEGs obtained from GSE76275 datasets. Furthermore, in the prognostic analysis of the 155 DEGs, we found that there were 10 genes associated with OS and 33 genes associated with RFS. Combined with the degree scores from the PPI network, a total of ten genes with the highest degree scores were selected as hub genes pertaining to TNBC.

Conclusion

Our research provides new insight into the subnetwork of biomarkers connected with TNBC, which could be useful for prognostication and risk stratification of TNBC patients.

Keywords

Triple-negative breast cancer Differentially expressed genes Protein–protein Interaction Kaplan–Meier plotter 

Abbreviations

TNBC

Triple-negative breast cancer

ER

Estrogen receptor

PR

Progesterone receptor

HER2

Human epidermal growth factor receptor 2

DEG

Differentially expressed genes

GEO

Gene expression omnibus

PPI

Protein–protein interaction

TCGA

The Cancer genome atlas

OS

Overall survival

RFS

Relapse-free survival

FC

Log fold control

EGFR

Epidermal growth factor receptor

KRT16

Keratin 16

RET

Ret proto-oncogene

SOX10

Sex-determining region Y-box 1

PDZK1

PDZ domain-containing 1

XBP1

X-box binding protein 1

TFF3

Trefoil factor 3

PTGER3

Prostaglandin E receptor 3

NME5

NME/NM23 family member 5

IL6ST

Interleukin 6 signal transducer

Notes

Author contributions

Conceived and designed the experiments and revised the manuscript: XMW, YY. Performed the experiments: QXZ, LPS, HL. Analyzed the data: QXZ, HL. Responsible for bioinformatics and bio-statistics analysis: QXZ, HL. Wrote the paper: QXZ.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48.CrossRefGoogle Scholar
  2. 2.
    Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Res. 2013;41:991–5.CrossRefGoogle Scholar
  3. 3.
    Davis Sean, Meltzer Paul S. GEO query: a bridge between the gene expression omnibus (GEO) and BioConductor. Bioinformatics. 2007;23(14):1846–7.CrossRefGoogle Scholar
  4. 4.
    Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3(1):Article3.CrossRefGoogle Scholar
  5. 5.
    Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta- Cepas J, et al. STRING v10: protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43:447–52.CrossRefGoogle Scholar
  6. 6.
    Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44(8):e71.CrossRefGoogle Scholar
  7. 7.
    Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139–40.CrossRefGoogle Scholar
  8. 8.
    Gyorffy B, Lanczky A, Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012;19(2):197–208.CrossRefGoogle Scholar
  9. 9.
    Pareja F, Geyer FC, Marchiò C, Burke KA, Weigelt B, Reis-Fiho JS. Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. NPJ Breast Cancer. 2016;2:16036.CrossRefGoogle Scholar
  10. 10.
    Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–67.CrossRefGoogle Scholar
  11. 11.
    Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012;136:331.CrossRefGoogle Scholar
  12. 12.
    Nakai K, Hung MC, Yamaguchi H. A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res. 2016;6:1609–23.Google Scholar
  13. 13.
    Hoadley KA, Weigman VJ, Fan C, Sawyer LR, He X, Troester MA, et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genom. 2007;8:258.CrossRefGoogle Scholar
  14. 14.
    Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–74.CrossRefGoogle Scholar
  15. 15.
    Burness ML, Grushko TA, Olopade OI. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? Cancer J. 2010;16:23–32.CrossRefGoogle Scholar
  16. 16.
    Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14(5):1368–76.CrossRefGoogle Scholar
  17. 17.
    Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012;30(21):2615–23.CrossRefGoogle Scholar
  18. 18.
    Joosse Simon A, Hannemann Juliane, Spotter Julia, Bauche Andreas, Andreas Antje, Muller Volkmar, et al. Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells. Hum Cancer Biol. 2012;18(4):993–1003.Google Scholar
  19. 19.
    Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;365:671–9.CrossRefGoogle Scholar
  20. 20.
    Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, et al. Genes that mediate breast cancer metastasis to the brain. Nature. 2009;459:1005–9.CrossRefGoogle Scholar
  21. 21.
    Morandi A, Plaza-Menacho I, Isacke CM. RET in breast cancer: functional and therapeutic implications. Trends Mol Med. 2011;17(3):149–57.CrossRefGoogle Scholar
  22. 22.
    Boulay A, Breuleux M, Stephan C, Fux C, Brisken C, Fiche M, et al. The ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer. Cancer Res. 2008;68(10):3743–51.CrossRefGoogle Scholar
  23. 23.
    Plaza-Menacho I, Morandi A, Robertson D, Pancholi S, Drury S, Dowsett M, et al. Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance. Oncogene. 2010;29(33):4648–57.CrossRefGoogle Scholar
  24. 24.
    Mechera R, Soysal SD, Piscuoglio S, Ng CKY, Zeindler J, Mujagic E, et al. Expression of RET is associated with Oestrogen receptor expression but lacks prognostic significance in breast cancer. BMC Cancer. 2019;19:41.CrossRefGoogle Scholar
  25. 25.
    Sarkar A, Hochedlinger K. The sox family of transcription factors: versatile regulators of stem and progenitor cell fate. Cell Stem Cell. 2013;12:15–30.CrossRefGoogle Scholar
  26. 26.
    Kim YJ, Lim H, Li Z, Oh Y, Kovlyagina I, Choi IY, Dong X, et al. Generation of multipotent induced neural crest by direct reprogramming of human postnatal fibroblasts with a single transcription factor. Cell Stem Cell. 2014;15:497–506.CrossRefGoogle Scholar
  27. 27.
    Dravis C, Spike BT, Harrell JC, Johns C, Trejo CL, Southard-Smith EM, et al. Sox10 regulates stem/progenitor and mesenchymal cell states in mammary epithelial cells. Cell Rep. 2015;12:2035–48.CrossRefGoogle Scholar
  28. 28.
    Dravis C, Spike BT, Harrell JC, Johns C, Trejo CL, Southard-Smith EM, et al. Sox10 regulates stem/progenitor and mesenchymal cell states in mammary epithelial cells. Cell Rep. 2015;12(12):2035–48.CrossRefGoogle Scholar
  29. 29.
    Kocher O, Comella N, Tognazzi K, Brown LF. Identification and partial characterization of PDZK1: a novel protein containing PDZ interaction domains. Lab Invest. 1998;78:117–25.Google Scholar
  30. 30.
    Kim H, Abd Elmageed ZY, Ju J, Naura AS, Abdel-Mageed AB, Varughese S, et al. PDZK1 is a novel factor in breast cancer that is indirectly regulated by estrogen through IGF-1R and promotes estrogen-mediated growth. Mol Med. 2013;19:253–62.CrossRefGoogle Scholar
  31. 31.
    Vic P, Vignon F, Derocq D, Rochefort H. Effect of estradiol on the ultrastructure of the MCF7 human breast cancer cells in culture. Cancer Res. 1982;42:667–73.Google Scholar
  32. 32.
    Shajahan AN, Riggins RB, Clarke R. The role of X-box binding protein-1 in tumorigenicity. Drug News Perspect. 2009;22(5):241–6.CrossRefGoogle Scholar
  33. 33.
    Chen X, Iliopoulos D, Zhang Q, et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway. Nature. 2014;508(7494):103–7.CrossRefGoogle Scholar
  34. 34.
    Li H, Chen X, Gao Y, Wu J, Zeng F, Song F. XBP1 induces snail expression to promote epithelial-to-mesenchymal transition and invasion of breast cancer cells. Cell Signal. 2015;27(1):82–9.CrossRefGoogle Scholar
  35. 35.
    Kjellev S. The trefoil factor family—small peptides with multiple functionalities. Cell Mol Life Sci. 2009;66(8):1350–69.CrossRefGoogle Scholar
  36. 36.
    May FE, Church ST, Major S, Westley BR. The closely related estrogen-regulated trefoil proteins TFF1 and TFF3 have markedly different hydrodynamic properties, overall charge, and distribution of surface charge. Biochemistry. 2003;42(27):8250–9.CrossRefGoogle Scholar
  37. 37.
    Ishibashi Yuko, Ohtsu Hiroshi, Ikemura Masako, Kikuchi Yasuko, Niwa Takayoshi, Nishioka Kotoe, et al. Serum TFF1 and TFF3 but not TFF2 are higher in women with breast cancer than in women without breast cancer. Sci Rep. 2017;7:4846.CrossRefGoogle Scholar
  38. 38.
    Cheuk IW, Shin VY, Siu MT, Tsang JY, Ho JC, Chen J, et al. Association of EP2 receptor and SLC19A3 in regulating breast cancer metastasis. Am J Cancer Res. 2015;5(11):3389–99.Google Scholar
  39. 39.
    Semmlinger A, von Schoenfeldt V, Wolf V, Meuter A, Kolben TM, Kolben T, et al. EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer. BMC Cancer. 2018;18:431.CrossRefGoogle Scholar
  40. 40.
    Puts GS, Leonard MK, Pamidimukkala NV, Snyder DE, Kaetzel DM. Nuclear functions of NME proteins. Lab Invest. 2018;98(2):211–8.CrossRefGoogle Scholar
  41. 41.
    Wu X, Tao P, Zhou Q, Li J, Yu Z, Wang X, et al. IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway. Oncotarget. 2017;8(13):20741–50.Google Scholar
  42. 42.
    Gyamf Jones, Lee Yun-Hee, Eom Minseob, Choi Junjeong. Interleukin-6/STAT3 signalling regulates adipocyte induced epithelial-mesenchymal transition in breast cancer cells. Sci Rep. 2018;8:8859.CrossRefGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2019

Authors and Affiliations

  1. 1.Department of Ultrasoundthe First Hospital of China Medical UniversityShenyangChina
  2. 2.Tumor Etiology and Screening Department of Cancer Institute and General Surgerythe First Hospital of China Medical UniversityShenyangChina
  3. 3.Key Laboratory of Cancer Etiology and Prevention (China Medical University), Liaoning Provincial Education Departmentthe First Hospital of China Medical UniversityShenyangChina

Personalised recommendations